Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma.-论文-万方医学网

第一作者： E K,Mai

第一单位： Department of Internal Medicine V, University Hospital Heidelberg and National Center for Tumor Diseases (NCT) Heidelberg on behalf of the German-Speaking Myeloma Multicenter Group (GMMG), Heidelberg, Germany.

作者： E K,Mai ^[1] ; U,Bertsch ^[1] ; J,Dürig ^[2] ; C,Kunz ^[3] ; M,Haenel ^[4] ; I W,Blau ^[5] ; M,Munder ^[6] ; A,Jauch ^[7] ; B,Schurich ^[8] ; T,Hielscher ^[3] ; M,Merz ^[9] ; B,Huegle-Doerr ^[1] ; A,Seckinger ^[1] ; D,Hose ^[1] ; J,Hillengass ^[9] ; M S,Raab ^[9] ; K,Neben ^[9] ; H-W,Lindemann ^[10] ; M,Zeis ^[11] ; C,Gerecke ^[12] ; I G H,Schmidt-Wolf ^[13] ; K,Weisel ^[14] ; C,Scheid ^[15] ; H,Salwender ^[16] ; H,Goldschmidt ^[1]

作者单位： Department of Internal Medicine V, University Hospital Heidelberg and National Center for Tumor Diseases (NCT) Heidelberg on behalf of the German-Speaking Myeloma Multicenter Group (GMMG), Heidelberg, Germany. ^[1] Department of Hematology, University Hospital Essen, Essen, Germany. ^[2] Division of Biostatistics, German Cancer Research Center (DKFZ) Heidelberg, Heidelberg, Germany. ^[3] Department of Internal Medicine III, Klinikum Chemnitz, Chemnitz, Germany. ^[4] Medical Clinic, Charité University Medicine Berlin, Berlin, Germany. ^[5] Department of Internal Medicine III, University Medical Center Mainz, Mainz, Germany. ^[6] Institute of Human Genetics, University of Heidelberg, Heidelberg, Germany. ^[7] Coordination Centers for Clinical Trials (KKS), University Hospital Heidelberg, Heidelberg, Germany. ^[8] Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany. ^[9] Department of Hematology and Oncology, Katholisches Krankenhaus Hagen, Hagen, Germany. ^[10] Department of Hematology, Asklepios Hospital St. Georg Hamburg, Hamburg, Germany. ^[11] Department of Hematology and Oncology, Helios Hospital Berlin Buch, Berlin, Germany. ^[12] Center for Integrated Oncology, University Hospital Bonn, Bonn, Germany. ^[13] Department of Hematology, Oncology and Immunology, University Hospital Tübingen, Tübingen, Germany. ^[14] Department of Internal Medicine I, University Hospital Köln, Köln, Germany. ^[15] Department of Hematology and Oncology, Asklepios Hospital Hamburg Altona, Hamburg, Germany. ^[16]

医学主题词成年人(Adult);老年人(Aged);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);硼酸化物(Boronic Acids);环磷酰胺(Cyclophosphamide);地塞米松(Dexamethasone);多柔比星(Doxorubicin);女(雌)性(Female);随访研究(Follow-Up Studies);造血干细胞动员(Hematopoietic Stem Cell Mobilization);人类(Humans);男(雄)性(Male);中年人(Middle Aged);多发性骨髓瘤(Multiple Myeloma);肿瘤分期(Neoplasm Staging);预后(Prognosis);前瞻性研究(Prospective Studies);吡嗪类(Pyrazines);缓解诱导(Remission Induction);存活率(Survival Rate)

DOI 10.1038/leu.2015.80

PMID 25787915

发布时间 2022-03-10

检索历史清除

Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma.

Leukemia

相似文献

同项目论文

Leukemia

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma.

Leukemia

相似文献

同项目论文

Leukemia

相关期刊

检索历史清除